- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 1, 2022Chambers USA Recognizes Five Robins Kaplan Practice Groups And 17 Lawyers In 2022 Guide
-
June 1, 2022Seasoned Attorney Joins Firm’s Business Litigation Group
-
May 26, 2022Shira Shapiro Named Woman of Promise By The Pearl Society
-
June 3, 202219th Annual Advanced Insurance Law
-
June 9, 2022Building Your Brand: Perspectives and Insights from a Diverse Bar
-
June 10, 2022LGBTQ Legal Services: Transgender Name Change Clinic
-
May 24, 2022Briefly: Seeking Fees and Costs While on Appeal
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
June 2, 2022Sandberg Stepping Down as Meta COO After 14 Years
-
June 1, 2022Markets Revert to Recent Form as Pessimism Takes Hold
-
May 27, 2022Unexpectedly Strong Retail Sales Pull Markets Back from the Brink
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Generic Launches
Reference Listed Drug, NDA Holder, Generic Drug Name, ANDA Applicant(s), Indication and Launch Date
Fall 2013

Reference Listed Drug |
NDA Holder |
Generic Drug Name |
ANDA Applicant(s) |
Indication |
Launch Date |
Maxalt MLT |
Merck |
Rizatriptan Benzoate Orally Disintegrating Tablets |
Glenmark Generics |
treatment of migraine headaches; Maxalt will only treat a headache that has already begun |
7/2/2013 |
Metrogel 1% |
Galderma Laboratories |
Metronidazole 1% topical gel |
Sandoz |
topical treatment of inflammatory lesions of rosacea |
7/2/2013 |
Evoxac |
Daiichi Sankyo |
Cevimeline Hydrochloride Capsules |
Roxane Laboratories |
treatment of dry mouth in people with Sjögren's Syndrome |
7/8/2013 |
Dacogen |
Eisai Inc. under license from Astex Pharmaceuticals |
Decitabine for Injection |
Dr. Reddy's Laboratories |
treatment of myelodysplastic syndromes (certain types of blood or bone marrow cancer) |
7/11/2013 |
Prandin |
Novo Nordisk |
Repaglinide Tablets |
Sun Pharmaceutical Industries |
adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus |
7/12/2013 |
Lamictal ODT |
GlaxoSmithKline |
Lamotrigine Orally Disintegrating Tablets |
Actavis |
treatment of epilepsy and bipolar disorder |
7/15/2013 |
Trilipix |
Abbott |
Fenofibric Acid Delayed-release Capsules |
Mylan Pharmaceuticals |
an adjunct to diet in combination with a statin to reduce triglyceride and increase high-density lipoprotein cholesterol in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their low-density lipoprotein cholesterol goal |
7/15/2013 |
Nor-Q.D. Tablets |
Watson Laboratories (now Actavis, Inc.) |
Norethindrone Tablets USP (0.35 mg) |
Mylan Pharmaceuticals |
prevention of pregnancy |
7/16/2013 |
Trilipix |
AbbVie |
Fenofibric Acid Delayed-release Capsules |
Par Pharmaceutical |
in combination with a statin to reduce TG and increase HDL-C in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL-C goal |
7/18/2013 |
Aricept |
Eisai Inc. under license from Eisai R&D Management |
Donepezil Hydrochloride Tablets |
Dr. Reddy's Laboratories |
treatment of mild to moderate dementia caused by Alzheimer's disease |
7/27/2013 |
Cutivate |
Fougera Pharmaceuticals |
Fluticasone Propionate Lotion, 0.05% |
Perrigo |
relief of inflammatory and pruritic manifestations of atopic dermatitis in patients 1 year of age or older |
7/31/2013 |
Micro-K 10 ExtenCaps |
Nesher Pharmaceuticals |
Potassium Chloride Extended-release Capsules |
Amneal Pharmaceuticals |
prevention of hypokalemia |
8/2/2013 |
Revatio |
Pfizer |
Sildenafil Tablets, USP |
Amneal Pharmaceuticals |
pulmonary arterial hypertension and improve exercise capacity in men and women. |
8/2/2013 |
Viramune |
Boehringer Ingelheim Pharmaceuticals |
Nevirapine Tablets, USP |
Amneal Pharmaceuticals |
treatment of HIV |
8/2/2013 |
Skelaxin |
King Pharmaceuticals Research and Development |
Metaxalone Tablets |
Amneal Pharmaceuticals |
muscle relaxant blocking nerve impulses in the brain |
8/2/2013 |
Coumadin |
Bristol-Myers Squibb |
Warfarin Sodium Tablets |
Amneal Pharmaceuticals |
treatment of venous thrombosis and its extension, pulmonary embolism (PE); thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement; and reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction |
8/2/2013 |
Derma-Smoothe |
Hill Dermac |
Fluocinolone Acetonide Scalp Oil, 0.01% |
Perrigo |
topical treatment of atopic dermatitis in adult patients and the topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks |
8/12/2013 |
Temodar |
Merck Sharp and Dohme |
temozolomide |
Teva Pharmaceuticals / Perrigo Company |
treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment and refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine |
8/12/2013 |
Temodar |
Merck Sharp and Dohme |
temozolomide capsules |
Sandoz |
treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment and refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine |
8/13/2013 |
Depakote ER |
Sanofi |
Divalproex Sodium Extended-release Tablets |
Dr. Reddy's Laboratories |
treatment of various types of seizure disorders; Divalproex sodium is sometimes used together with other seizure medications |
8/19/2013 |
Opana ER |
Endo-Health Solutions |
Oxymorphone Hydrochloride Extended-release Tablets |
Actavis |
relief of moderate to severe pain in patients requiring continuous around-the-clock opioid treatment for an extended period of time |
9/12/2013 |
Prevacid |
Takeda Pharmaceuticals U.S.A. |
Lansoprazole Delayed-release Capsules |
Sun Pharmaceutical |
short-term treatment (for 4 week) for healing and symptom relief of active duodenal ulcer |
9/14/2013 |
Niaspan |
AbbVie |
Niacin Extended-release Tablets |
Teva Pharmaceutical Industries |
reduce elevated TC, LDL-C, Apo B and TG levels and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia |
9/20/2013 |
Nitrolingual Pumpspray |
Pohl Boskamp |
Nitroglycerin Spray, 400 mcg/spray |
Perrigo |
acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease |
9/23/2013 |
Vidaza |
Celgene |
Azacitidine for Injection |
Sandoz |
treatment of myelodysplastic syndrome (MDS) |
9/23/2013 |
Adenoscan |
Astellas Pharmaceuticals |
Adenosine Injection |
Teva Pharmaceutical Industries |
adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately |
9/24/2013 |
Glucotrol XL |
Pfizer |
Glipizide Extended-release Tablets |
Par Pharmaceutical |
as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus |
9/25/2013 |
Vfend |
Pfizer |
Voriconazole for Oral Suspension |
Mylan Pharmaceuticals |
triazole antifungal drug |
9/30/2013 |
Related Professionals
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.